Taking nature’s lead
in antimicrobials

Grant Support for Lynovex
04-Dec-2018

NovaBiotics Featured in BIA Guide to Antimicrobial Resistance
26-Oct-2018

NovaBiotics at North American Cystic Fibrosis Conference (NACFC), Denver 2018
17-Oct-2018

Data on the mucolytic mechanism of action of Lynovex will be presented at NACFC 2018.
20-Jul-2018

CARE CF 1 Lynovex clinical trial data selected for presentation at NACFC 2018.
20-Jul-2018

Positive Top Line Data from the CARE CF 1 Clinical Study of Oral Lynovex in Cystic Fibrosis Exacerbations
10-Jul-2018

NovaBiotics CEO named as one of the top 30 woman leaders in UK healthcare
14-Jun-2018

Cysteamine, an endogenous aminothiol, and cystamine, the disulfide product of oxidation, increase Pseudomonas aeruginosa sensitivity to reactive oxygen and nitrogen species and potentiate therapeutic antibiotics against bacterial infection.
03-Apr-2018

How Lynovex works to boost antibiotics in combatting Pseudomonas aeruginosa infection in cystic fibrosis
19-Mar-2018

NovaBiotics’ Lynovex receives Fast Track Designation for Cystic Fibrosis Exacerbations
12-Mar-2018

NovaBiotics Chief Executive Officer Elected as a Fellow of the Royal Society of Edinburgh
27-Feb-2018

NovaBiotics and BioPharma Dealmakers’ ‘Fighting Infectious Diseases’ Webcast
22-Feb-2018

NovaBiotics Receives Most Innovative EU Biotech SME 2017 Award
23-Nov-2017

Enrolment reaches 50% in Lynovex CARE-CF-1 trial
02-Nov-2017

NovaBiotics at North American Cystic Fibrosis Conference (NACFC), Indianapolis
30-Oct-2017

Reflections from World AMR Congress
19-Oct-2017

EuropaBio announces the finalists for the Most innovative European Biotech SME Awards 2017
18-Oct-2017

NovaBiotics at World Antimicrobial Resistance Congress, Washington
13-Sep-2017

NovaBiotics at ASM/ESCMID Conference
31-Aug-2017

NovaBiotics at the 7th International Meeting on Antimicrobial Peptides
21-Aug-2017

NovaBiotics Chief Executive responds to Public Health England warning on Candida auris fungus
16-Aug-2017

NovaBiotics featured on STV News
04-Aug-2017

New Drug Kills MRSA – including strains with antibiotic resistance
03-Aug-2017

50th patient recruited for CARE- CF-1 Lynovex clinical study
01-Aug-2017

NovaBiotics’ novel antimicrobial Luminaderm highly effective against Multi drug resistant MRSA
16-Jun-2017

NovaBiotics participating in BIO 2017 in San Diego
15-Jun-2017

NovaBiotics at European Cystic Fibrosis Conference in Seville
06-Jun-2017

NovaBiotics at American Society for Microbiology
26-May-2017

30 subjects now randomised in Lynovex CARE-CF-1 trial
10-May-2017

NovaBiotics contribution to ECCMID 2017
13-Apr-2017

NovaBiotics Quality Management System Achieves ISO 9001 certification
11-Apr-2017

NovaBiotics to host live Twitter Lynovex Q&A
24-Mar-2017

NovaBiotics Chief Executive Addresses 'Superbugs & Superdrugs' Conference on Antimicrobial Drug Discovery
21-Mar-2017

NovaBiotics CEO to speak at 19th Superbugs & Superdrugs Conference
17-Mar-2017

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
03-Mar-2017

NovaBiotics CEO to speak at 10th Berlin Conference on Life Sciences
21-Feb-2017

NovaBiotics at ECCMID 2017
25-Jan-2017

NovaBiotics CEO featured as one of 15 women leading in European Biotech
18-Jan-2017

NovaBiotics announces first patients dosed in Lynovex clinical study
16-Jan-2017

Commercial Collaboration Deal for (Oral) Lynovex®
05-Aug-2016

NovaBiotics "one to watch" for 2017
14-Jul-2016

NovaBiotics Announces New Data on Cysteamine (Nylexa™) as an Antimicrobial Resistance Breaker in Multi Drug Resistant Bacteria
18-Jun-2016

NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance
07-Jun-2016

NovaBiotics Discusses Innovation for Antimicrobial Resistance at BIO
03-Jun-2016

Lynovex Clinical Trial Data Published
12-May-2016

NovaBiotics wins Investment of the Year
05-Feb-2016

Sad news on NovaBiotics' co-founder and first Chairman
10-Sep-2015

Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus
12-Aug-2015

Positive Lynovex Phase IIa data presented at the 38th European Cystic Fibrosis Symposium
12-Jun-2015

NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management
19-Jan-2015

Dr Deborah O’Neil Named EY UK Health Products & Services Entrepreneur of 2014
07-Oct-2014

NovaBiotics Receives Orphan Drug Status from FDA
16-Sep-2014

Initiation of a Phase IIa Clinical Study for Lynovex® in Cystic Fibrosis
25-Jun-2014

NovaBiotics’ Dr Deborah O’Neil Named as an EY Scotland Entrepreneur of 2014
20-Jun-2014

Collaboration between NovaBiotics and the Cystic Fibrosis Trust
31-Jan-2014

NovaBiotics’ Lynovex® Gains Support From The UK’s Cystic Fibrosis Trust
30-Oct-2013

NovaBiotics Enters into Agreement with Taro
24-Aug-2013

Excellent Results From the Unblinding of the Novexatin® Phase IIa Clinical Trial
08-Jul-2010

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including Lynovex (in oral and inhaled form), an orphan drug candidate for cystic fibrosis (CF), Novexatin, a potential step change therapy for onychomycosis (being co-developed with and out-licensed to Taro Pharmaceuticals) and Novamycin, a novel antifungal peptide in development primarily for the treatment of invasive fungal diseases caused by mould & emerging, drug resistant yeasts. Novexatin and Novamycin are among the first in class peptide anti-infectives which the company continues to derive from its proprietary antimicrobial peptide rational drug design platform.  Lynovex and Nylexa have been developed as novel antimicrobial adjunct therapies from the company's more recently established aminothiol platform.